Podcast: Immune Persistence After Primary Vaccination with MenQuadfi Authors: Mika Rämet, Mike Simon Published: 2026 ABSTRACT Invasive meningococcal disease (IMD) remains a serious global health concern. Although incidence is generally low, the disease progresses rapidly and carries high fatality rates of 10–15%, with survivors often experiencing long-term sequelae including hearing loss, neurological impairment, or limb amputations. These consequences highlight the need for effective and durable vaccination strategies. IMD incidence and serogroup distribution vary geographically. The highest burden occurs in the African meningitis belt, historically dominated by serogroup A, though recent outbreaks have increasingly involved serogroups C, W, and X. In Europe, serogroup B is most common, particularly in infants and adolescents, while serogroup Y is rising among adults aged ≥ 65 years. These geographical and demographic differences underscore the importance of region-specific vaccination policies. Polysaccharide vaccines targeting serogroups A, C, W, and Y have played an essential role in outbreak control but are associated with certain limitations: they do not induce immune memory and are poorly immunogenic in infants. These limitations led to the development of conjugate vaccines, where polysaccharide antigens are linked to protein carriers to enhance immunogenicity and memory responses. Several quadrivalent conjugate vaccines (MenACWY), MenQuadfi®, Menveo®, and Nimenrix®, are available, which target the same four serogroups, but differ in antigen composition and carrier proteins. However, access to meningococcal vaccines varies across regions. In this podcast, Professor Mika Rämet and Dr Mike Simon discuss the concept of immune persistence and its relevance for evaluating long-term protection provided by quadrivalent meningococcal vaccines. They review persistence data for MenQuadfi from recent clinical trials and a modeling study across multiple age groups and timepoints, comparing these findings with persistence data for other quadrivalent vaccines. Overall, the evidence supports the use of MenQuadfi as a MenACWY option, including for children, to help provide and maintain protection against IMD in the years following primary vaccination.Podcast available for this article. Supplementary material 1 (MP2 156850 kb)Electronic supplementary materialThe online version of this article (10.1007/s40121-026-01370-z) contains supplementary material, which is available to authorized users. Key Summary Points Invasive meningococcal disease (IMD) is rare but severe. Meningococcal infection can progress rapidly, is associated with high fatality rates (10–15%), and can lead to significant long-term complications in up to 20% of survivors, underscoring the importance of durable vaccination.IMD incidence and serogroup distribution vary geographically, with serogroups B, C, W, X and Y contributing substantially to the disease burden in many settings.There are several available quadrivalent conjugate vaccines that target the same four serogroups (A, C, W, and Y)—MenQuadfi®, Menveo®, and Nimenrix®; however, they differ in antigen composition and carrier proteins and access to these vaccines varies widely across regions.Data for MenQuadfi demonstrate immune persistence following primary vaccination across age groups and compares favorably with other quadrivalent vaccines.Evidence supports the use of MenQuadfi as a MenACWY option, including for children, with the potential to help maintain protection in the years following primary vaccination. Invasive meningococcal disease (IMD) is rare but severe. Meningococcal infection can progress rapidly, is associated with high fatality rates (10–15%), and can lead to significant long-term complications in up to 20% of survivors, underscoring the importance of durable vaccination.IMD incidence and serogroup distribution vary geographically, with serogroups B, C, W, X and Y contributing substantially to the disease burden in many settings.There are several available quadrivalent conjugate vaccines that target the same four serogroups (A, C, W, and Y)—MenQuadfi®, Menveo®, and Nimenrix®; however, they differ in antigen composition and carrier proteins and access to these vaccines varies widely across regions.Data for MenQuadfi demonstrate immune persistence following primary vaccination across age groups and compares favorably with other quadrivalent vaccines.Evidence supports the use of MenQuadfi as a MenACWY option, including for children, with the potential to help maintain protection in the years following primary vaccination. Podcast Content The podcast video can be downloaded from the article’s Figshare page here: 10.6084/m9.figshare.32261505. Alternatively, you can stream the podcast by searching for ‘Adis Journal Podcasts’ on your preferred podcast platform. Podcast Transcript Introduction MR: I’m Mika Rämet, I’m Professor of Experimental Immunology, at the University of Tampere, Finland, and I’m also a Professor of Pediatrics at the University of Oulu, Finland. And it’s really nice to participate in this podcast. MS: I’m Dr Mike Simon, I’m Professor of Pediatrics at the University of Kentucky, and I own and operate my own private pediatric practice in Lexington. Aims MR: The aims of this podcast are to explain the concept of immune persistence and its importance in long-term protection offered by quadrivalent meningococcal vaccines, in addition, to present the persistence data for MenQuadfi® taken from recently published clinical trials and modeling studies for different time points and age groups, and, finally, [to] compare the reported and modeled persistence rates for MenQuadfi to other quadrivalent meningococcal vaccines. Background to Meningococcal Disease and Quadrivalent Vaccines MR: First, some background [information] to meningococcal disease and quadrivalent vaccines in general. Invasive meningococcal disease is rather rare; however, for those who are affected, it’s a devastating infection; disease progresses rapidly and can become life threatening in hours. Even with appropriate treatment case fatality rates remain unfortunately high, roughly 10–15%. And up to 20% of survivors experience serious long-term complications such as hearing loss, neurological impairment, cognitive difficulties, or even limb amputations [1, 2]. Furthermore, while the overall incidence of invasive meningococcal disease is relatively low in developed countries like Finland and the US, the invasive meningococcal disease is far more common in other areas, especially in Africa [1, 3–5]. The so-called African meningitis belt, stretching from Senegal in the west to Ethiopia in the east, remains the region with the highest incidence worldwide [4]. In summary, invasive meningococcal disease remains a global health threat and prevention through effective vaccination programs is of paramount importance. Meningococcal diseases are caused by different types of Neisseria meningitidis bacteria, which are called serogroups. Historically, outbreaks in Africa were driven primarily by serogroup A. However, more recent outbreaks involved other serogroups such as C, W, and X [4]. Prevalence of different serogroups is also constantly shifting in Europe, while serogroup B predominates, particularly among infants and adolescents, the serogroup Y is increasingly seen in older adults [5]. At the same time, serogroup W has been rising globally. That means that these regional temporal age-specific and serogroup-specific differences underline the importance of tailoring vaccination programs to local epidemiology [1–5]. Looking briefly at the history of meningococcal vaccines, early efforts focused on polysaccharide vaccines targeting, understandably, the most important serogroups, A, C, W, and Y [6]. These vaccines were instrumental in controlling outbreaks. However, they have significant limitations; namely, polysaccharide vaccines do not induce proper immune memory and are poorly immunogenic in infants, who are unfortunately one of the highest-risk groups for meningococcal disease [7, 8]. These shortcomings were largely overcome with the development of so-called "conjugate" vaccines. In these vaccines, the polysaccharide antigens are chemically linked to a protein carrier, enhancing immunogenicity and enabling immune memory [8]. Over time, several "conjugate" vaccines have been developed targeting serogroups A, C, W, and Y [6–8]. In this podcast, we will discuss mainly the following meningococcal vaccines: MenQuadfi, which is manufactured by Sanofi, Menveo®, which is produced by GlaxoSmithKline, and Nimenrix®, manufactured by Pfizer. While these vaccines target the same four serogroups, A, C, W, and Y, they differ in antigen content and in their carrier protein used [6–9]. MenQuadfi, for example, features a novel design with tailored conjugation for each individual serogroup, representing an important evolution in quadrivalent vaccine development [10]. It is important to note that serogroup B is not targeted by the quadrivalent vaccines discussed in this podcast. Current access to meningococcal vaccines varies significantly between different countries and regions [9, 11–15]. For example, in the US, quadrivalent meningococcal vaccines are routinely available, but access to MenB vaccines is less consistent [9, 11–13]. In Europe, uptake is higher in countries where vaccines are publicly funded and included in national immunization programs [14]. In low-income countries, access remains limited with only a portion of countries offering routine meningococcal vaccination for specific age groups [15]. In summary, although invasive meningococcal disease is relatively uncommon, at least in Europe and in the US, its severity and evolving epidemiology requires sustained attention and adaptable vaccination strategies tailored to [the] local situation. After this, I will hand over to Professor Simon. What is Immune Persistence After Meningococcal Vaccination and Why is it Important? MS: Thank you very much, I’d like to continue. Maintaining high levels of circulating antibodies against rapidly progressing diseases, especially invasive Neisseria meningitidis, is critical [16]. The incubation period for meningococcal exposure to the onset of invasive illness can be as short as only 3–4 days. It may then progress from fulminant disease to death in over just a matter of hours [4]. The immune response may take 4–5 days to produce effective antibody levels and simply cannot respond quick enough to counter the rapidly invasive effects of this bacterium. So this underscores why maintaining circulating functional antibodies, especially for Neisseria meningitidis, is critical [16]. So, how do we do this? Well, we do it by [administering] vaccinations. The goal of meningococcal vaccinations is to help induce and sustain protection by maintaining effective antibody titers. This is achieved through a primary vaccination and initial doses, followed by a booster to preserve protective antibody levels [7, 16]. For Neisseria meningitidis, maintaining high levels of circulating antibodies is a critical component of long-term protection, far more important than for slowly progressing infections [16]. We need the activity of both our antibodies and complement to destroy Neisseria meningitidis [16]. We have an in vitro assay that replicates what naturally happens in vivo, a serum bactericidal activity assay. This assay includes an individual’s serum containing anti-meningococcal antibodies, a standardized concentration of either rabbit or human complement, and a measured number of Neisseria meningitidis bacteria [17, 18]. Rabbit complement and human complement are not physiologically identical, and results will differ and make comparing different clinical trials confusing. Human complement more accurately replicates in vitro what happens in vivo. When evaluating meningococcal vaccine effectiveness, it is important to know which complement was used and to keep in mind these differences of both human and rabbit complement [18]. MR: Thank you, Professor Simon. Editorial Note Added for Clarity and Not Part of the Recording It is important to note that regulatory agencies in clinical trials apply different thresholds for human and rabbit serum bactericidal assays when defining individual protection levels. Whilst human complement is a key metric in these discussions, rabbit complement data have also been studied and generated for all the clinical trials and the modeling study discussed here and provided the same trends in immune response [18]. Summary of Main Results Obtained on MenQuadfi Persistence in Recently Published Clinical Trials MR: Next, we’ll be discussing the immune persistence of MenQuadfi based on the recently published phase III clinical trials and what this means for long-term protection against invasive meningococcal disease [17, 19–23]. These studies evaluated both the immune response to a MenQuadfi booster dose, as well as the persistence of antibodies from the primary vaccine at day zero (that is right before the booster dose) [17, 19–23]. Let’s start with the children aged 4–7 years. In young children, the immune persistence of MenQuadfi vaccine was evaluated in the MET62 study [19]. This study enrolled children aged 4–5 years who had received a single dose of MenQuadfi or another meningococcal vaccine 3 years earlier. Three years after primary MenQuadfi vaccination, the majority of children had protective antibody titers, before receiving the booster dose. Specifically, protection was retained for 98–100% of participants against serogroups C, W, and Y, and about 70% for serogroup A [19]. Similar results were also obtained in another study, called MEQ73, which was carried out 5-years post-vaccination in children who were about 6–7 years of age at the time of the study. Before receiving a booster dose, antibody titers for all four meningococcal serogroups, A, C, W, and Y, were still higher than they had been before the original infant vaccination, indicating that immune responses had persisted 5 years after the primary dose [20]. After administration of [a] MenQuadfi booster, nearly all children showed protective antibody levels against all four serogroups. Seroprotection rates were very high, about 99% for serogroup A, 98% for C, and 100% for both W and Y [20]. This robust increase confirms that the immune system was effectively primed and ready to respond years later. Antibody titers remained higher compared to pre-vaccination levels. On the day of booster administration, seroprotection had declined slightly for C and Y but remained stable for A and W, with roughly 75–85% of children still protected [20]. Next, let’s discuss what we know related to adolescents and young adults, aged 13–25. The MET59 study included adolescents and young adults, aged between 13–24 at the time of the study, who had received a primary MenQuadfi vaccination 3–6 years earlier [21]. The study showed durable immune persistence before the booster dose. Protective antibody levels remained high for all four meningococcal serogroups, levels were well above pre-vaccination baseline, demonstrating long-term immune memory. After administration of MenQuadfi booster, virtually all participants achieved protective antibody levels against all four serogroups, confirming a strong and rapid immune response [21]. Finally, in older adults, aged 56 and above, immune persistence was studied in the MEQ66 trial [17, 23], [showing that], 5–7 years after primary vaccination, antibody titers for C, W, and Y declined as expected, but remained above pre-vaccination levels. Serogroup A levels at 5 years were comparable to baseline. When MenQuadfi booster dose was given to these adults, antibody levels increased robustly for all four serogroups. In participants who had originally been primed with MenQuadfi, both the post-booster antibody levels and seroprotection rates were higher, or there was at least a clear trend towards higher response compared with those primed with a polysaccharide meningococcal vaccine [17, 23]. In summary, the evidence from phase III trials shows that MenQuadfi maintains robust immune responses over multiple years for children, adolescents, young adults, and older adults [17, 19–23]. This finding supports its use in protecting populations from invasive meningococcal disease. However, it is important to acknowledge the limitations. First, while antibody titers are widely accepted as correlates of protection, the clinical significance of specific titers has not been fully determined. Second, additional post-license studies and continued real-world surveillance are needed to confirm the vaccine’s effectiveness against actual infection and against severe disease, in particular. Comparing Persistence Data Across Different Quadrivalent Meningococcal Vaccines MS: Thanks, Dr Rämet. The question does come up as far as persistence of antibody titers, and we can look at the information you presented from the clinical trials. Some general observations are, first of all, not every participant maintained protective antibody titers for all serogroups. However, those primed with MenQuadfi consistently had higher circulating antibody titers compared to those primed with a different quadrivalent meningococcal vaccine [17, 19–23]. We must, however, caution that measurable antibody levels do not always correlate with seroprotection. Just because you have a measurable antibody titer, it may not be high enough to produce protection [16, 18]. Looking at several different data points, we can actually quantify how antibody levels change over time. Comparing the circulating antibody levels 30 days after receipt of the primary dose to levels measured just before the MenQuadfi booster dose, there was a decline in the circulating antibody titers [17, 19–23]. This is consistent with what has been typically observed after meningococcal vaccinations [7]. Antibody levels measured just before the booster dose are higher than the pre-primary dose levels. This indicates that, for many participants, circulating antibodies will persist over time [17, 19–23]. While the focus of our discussion at this point is immune persistence, I would like to add that it is reassuring to see that these studies also corroborated the idea that quadrivalent meningococcal conjugate vaccines are interchangeable for the primary dose. With respect to dosing, specifically, MenQuadfi was able to induce a booster response regardless of the quadrivalent meningococcal conjugate vaccination used for priming [17, 19–23]. This has real-world implications because patients may change healthcare providers and not receive the same product for priming and booster doses, and also providers may from time-to-time change/switch vaccine purchasing contracts. I just wanted to follow up on some additional information: when I give my patients a quadrivalent meningococcal vaccination, I know they will have high levels of circulating antibody produced and protection from meningococcal disease. However, this protection will decline as antibody titers decline naturally over time. I need to know, and every healthcare provider who administers these vaccinations needs to know, when our patients should receive a booster vaccination to maintain their circulating antibody titers [7, 16]. And, amazingly enough, there have been several models developed to answer this question. Here’s a Bayesian approach. Coudeville and associates developed two models that projected the trajectory of antibody decline over a 10-year period [9]. We can break down the data for the predicted outcome for seroprotection at 10 years following the vaccination by age, the vaccination given, and serogroup cohorts. For toddlers, the seroprotection rate was estimated to be at least fivefold greater for serogroup C and almost doubled for serogroup W for those receiving MenQuadfi compared to Nimenrix. For serogroup C, it was 77% for MenQuadfi versus 17% for Nimenrix, and, for serogroup W, it was 67% for MenQuadfi versus 36% for Nimenrix [9]. For adolescents and young adults, seroprotection rates were more than 50% higher with MenQuadfi versus Menveo for serogroup C and about 15% higher for serogroup W. For serogroup C, 63% for MenQuadfi versus 40% for Menveo. For serogroup W, 67% for MenQuadfi versus 57% for Menveo. For serogroups A and Y, there was no significant difference in seroprotection rates with either vaccination 10 years after the last vaccination [9]. For the older patients, seroprotection rates for both C and W were around 30% higher with MenQuadfi versus Menomune. for serogroup C, 31% for MenQuadfi versus 22% for Menomune; for serogroup W, 38% for MenQuadfi versus 20% for Menomune; and, for MenQuadfi versus Menomune, seroprotection rates were comparable for serogroups A and Y [9]. With all that information, the bottom line is that, across all cohorts, MenQuadfi demonstrates durable immune persistence, with higher predicted protection for serogroups C and W, and equivalent protection for serogroups A and Y, compared to other quadrivalent meningococcal vaccines [9]. This information will help to guide optimal booster timing and reinforce MenQuadfi’s role in long-term protection strategies. MR: Thank you, Professor Simon. Clinical Implications and Future Perspectives MR: So, from a clinical perspective, there are some factors that need to be considered. The risk of invasive meningococcal disease has distinct peaks at certain ages. First, infants and young children, those who are typically younger than 1 or 2 years of age; this is the highest risk group overall. In many countries, serogroup B predominates in this age group [5]. Then, the next peak is among adolescents and young adults who are between 15 and 25 years of age. The reason for this peak is that young adults live typically in close contact settings like dormitories or military barracks with increased transmission. Serogroups B, C, W, and Y are more common among this group. Then, the third peak is among older adults who are more than 50–60 years of age. Although less frequent than in infants or adolescents, case fatality rates are higher, meaning that infections are more likely to be severe or even fatal among this age group. Serogroups W and Y are more often involved in older adults [5]. So what does this mean in the context of quadrivalent meningococcal vaccines such as MenQuadfi? Data from the MET59 study consisting of adolescents and young adults support the schedule where a primary MenQuadfi dose is given at 11–12 years of age followed by booster 3–6 years later [21]. A sub-analysis of this study also showed that priming at 10–12 years of age maintains protective antibody levels up to the recommended booster age of around 16, confirming the schedule provides coverage when adolescents need it the most [22]. Persistence data are also encouraging for older adults who face a third incidence peak and higher case fatality rates [9, 17]. Durable immunity in this group could address an important unmet medical need. Looking ahead, ongoing studies like MEQ73 in toddlers will provide 10-year persistence data, hopefully helping to inform the best strategies for meningococcal vaccination across all age groups. Summary and Concluding Remarks MR: As a final remark, only a vaccine which has been administered is effective. The immune persistence data not only confirm long-term protection of a given vaccine such as MenQuadfi but also help policymakers design cost-effective vaccination schedules that keep populations safe and as healthy as possible. Overall, these findings from multiple recently published clinical studies together with a modeling analysis support the use of MenQuadfi in routine vaccination schedules, including those for children and adolescents, and help provide protection against invasive meningococcal disease during the years following primary vaccination. So, Professor Simon, these results are really intriguing. How do you see the clinical importance of these studies and results so far? MS: The data reinforce that effective short- and long-term protection will occur with meningococcal vaccinations. Also, the data show that optimal protection occurs with MenQuadfi when it's used for both the primary and the booster dose. So, this information, I think, will be important in the strategic planning for meningococcal vaccinations moving forward, looking at different age cohorts, and especially the benefit of the proper timing for boosting. MR: Yes, this sounds really exciting and important, and I think this is a major step forward in attempts to lower the disease burden caused by meningococcal diseases. Thank you. I think that’s all at this point. MS: I would like to thank everyone for this activity. I’d like to thank Sanofi for their support and sponsorship of this presentation. I’d like to thank everyone, especially Dr. Rämet, involved in coordinating and the mechanics of making this happen. I would like to especially thank those listening to the podcast, and hopefully you’ll find this information presented both helpful and informative. MR: Yes, and on my behalf as well, I want to thank all the staff who have participated in these trials, and of course Sanofi for providing the sponsorship, and, in particular, all the participants in these trials. It’s really, really important that we can advance medicine through these high-quality clinical trials.